Enochian Biosciences Inc.

3.07-0.0400-1.29%Vol 150.20K1Y Perf -17.07%
Apr 19th, 2021 16:00 DELAYED
BID3.07 ASK3.10
Open3.14 Previous Close3.11
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap146.63M 
Earnings Rating
Neutral
Price Range Ratio 52W %
4.34 
Earnings Date
10th May 2021

Today's Price Range

3.003.24

52W Range

2.6013.43

5 Year PE Ratio Range

-13.50-12.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
3.37%
1 Month
-21.28%
3 Months
-7.53%
6 Months
-8.08%
1 Year
-17.07%
3 Years
-38.48%
5 Years
56.33%
10 Years
-

TickerPriceChg.Chg.%
ENOB3.07-0.0400-1.29
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.03-
Q01 2020--0.09-
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date10th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume150.20K
Shares Outstanding47.76M
Trades Count817
Dollar Volume462.39K
Avg. Volume266.52K
Avg. Weekly Volume138.78K
Avg. Monthly Volume555.64K
Avg. Quarterly Volume286.67K

Enochian Biosciences Inc. (NASDAQ: ENOB) stock closed at 3.07 per share at the end of the most recent trading day (a -1.29% change compared to the prior day closing price) with a volume of 150.37K shares and market capitalization of 146.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Enochian Biosciences Inc. CEO is Mark R. Dybul.

The one-year performance of Enochian Biosciences Inc. stock is -17.07%, while year-to-date (YTD) performance is 4.07%. ENOB stock has a five-year performance of 56.33%. Its 52-week range is between 2.6 and 13.43, which gives ENOB stock a 52-week price range ratio of 4.34%

Enochian Biosciences Inc. currently has a PE ratio of -13.50, a price-to-book (PB) ratio of 0.91, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -5.96%, a ROC of -6.23% and a ROE of -6.28%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Enochian Biosciences Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Enochian Biosciences Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Enochian Biosciences Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Enochian Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enochian Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enochian Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.46, ATR14 : 0.32, CCI20 : -56.82, Chaikin Money Flow : -0.35, MACD : -0.17, Money Flow Index : 35.95, ROC : -13.28, RSI : 56.14, STOCH (14,3) : 26.92, STOCH RSI : 0.27, UO : 43.89, Williams %R : -73.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enochian Biosciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Enochian Biosciences Inc.

Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in identifying, developing, manufacturing, and commercializing gene therapies. The company develops cures and providing prevention for infectious diseases and cancer. It is also engaged in developing HIV preventative vaccine and cures and Cellular immune-oncology products.

CEO: Mark R. Dybul

Telephone: +1 786 888-1685

Address: 2080 Century Park East, Los Angeles 90067-2012, CA, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

52%48%

Bearish Bullish

52%48%

News

Stocktwits